T3 Mycin Use In Pregnancy & Lactation

Usage in pregnancy: Safety for use in pregnancy has not been established.
Nursing mothers: It is not known whether Clindamycin is excreted in human milk following use of Clindamycin Gel. However, orally and parenterally administered Clindamycin has been reported to appear in breast milk. As a general rule, nursing should not be undertaken while a patient is on drug since many drugs are excreted in human milk. When significant diarrhoea occurs, the drug should be discontinued. Clindamycin Phosphate should be prescribed with caution in atopic individuals. Orally and parenterally administered Clindamycin has been associated with severe colitis which may result in patient death. Use of topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface. Diarrhoea, bloody diarrhoea and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic Clindamycin. Studies indicated a toxin(s) produced by clostridia is one primary cause of antibiotic associated colitis. The colitis is usually characterized by severe persistent diarrhoea and severe abdominal cramps and may be associated with the passage of blood and mucous. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. When significant diarrhoea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in case of severe diarrhoea.